HealthEquity (HQY) vs. Its Peers Critical Survey
HealthEquity (NASDAQ: HQY) is one of 18 public companies in the “Medical Software & Technology Services” industry, but how does it compare to its peers? We will compare HealthEquity to similar companies based on the strength of its earnings, profitability, dividends, risk, analyst recommendations, institutional ownership and valuation.
This is a breakdown of recent recommendations for HealthEquity and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
HealthEquity currently has a consensus price target of $57.00, indicating a potential upside of 20.97%. As a group, “Medical Software & Technology Services” companies have a potential upside of 16.81%. Given HealthEquity’s stronger consensus rating and higher possible upside, analysts clearly believe HealthEquity is more favorable than its peers.
Risk & Volatility
HealthEquity has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, HealthEquity’s peers have a beta of 1.33, indicating that their average stock price is 33% more volatile than the S&P 500.
This table compares HealthEquity and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
91.0% of HealthEquity shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 19.0% of HealthEquity shares are owned by insiders. Comparatively, 21.9% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares HealthEquity and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|HealthEquity||$202.47 million||$61.84 million||70.33|
|HealthEquity Competitors||$376.98 million||$34.79 million||8.83|
HealthEquity’s peers have higher revenue, but lower earnings than HealthEquity. HealthEquity is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
HealthEquity beats its peers on 10 of the 13 factors compared.
HealthEquity, Inc. provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions. Its platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives and make educated investment choices to help in their tax-advantaged healthcare savings. Its products and services include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements and healthcare incentives. Its ecosystem primarily consists of HSA.
Receive News & Stock Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related stocks with our FREE daily email newsletter.